Flexion Therapeutics (NASDAQ:FLXN) Upgraded to “Sell” at BidaskClub

Flexion Therapeutics (NASDAQ:FLXN) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Friday, BidAskClub reports.

A number of other research firms have also recently commented on FLXN. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, December 31st. Raymond James increased their price target on Flexion Therapeutics from $25.00 to $28.00 and gave the company a “strong-buy” rating in a research note on Friday, December 27th. Benchmark increased their price target on Flexion Therapeutics from $19.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, December 27th. BMO Capital Markets reiterated a “buy” rating and issued a $29.00 price target on shares of Flexion Therapeutics in a research note on Friday, December 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of Flexion Therapeutics in a research note on Friday, December 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $24.33.

Shares of FLXN stock opened at $8.75 on Friday. Flexion Therapeutics has a 1-year low of $5.01 and a 1-year high of $22.98. The stock’s 50-day moving average is $13.65 and its 200 day moving average is $16.07. The company has a market cap of $345.79 million, a P/E ratio of -2.23 and a beta of 1.49. The company has a debt-to-equity ratio of 27.76, a current ratio of 5.40 and a quick ratio of 4.95.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Thursday, March 12th. The specialty pharmaceutical company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.07. Flexion Therapeutics had a negative return on equity of 592.50% and a negative net margin of 205.29%. The company had revenue of $23.65 million during the quarter, compared to analysts’ expectations of $23.50 million. On average, analysts anticipate that Flexion Therapeutics will post -3.07 EPS for the current year.

Several large investors have recently made changes to their positions in FLXN. Artisan Partners Limited Partnership purchased a new position in shares of Flexion Therapeutics in the fourth quarter worth about $17,326,000. State Street Corp raised its stake in shares of Flexion Therapeutics by 12.4% in the fourth quarter. State Street Corp now owns 1,665,898 shares of the specialty pharmaceutical company’s stock worth $34,484,000 after purchasing an additional 183,257 shares during the last quarter. Madison Asset Management LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter worth about $3,426,000. Castleark Management LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter worth about $3,399,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Flexion Therapeutics in the fourth quarter worth about $2,334,000. Hedge funds and other institutional investors own 83.58% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Further Reading: How is inflation measured?

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.